Hyrum Davenport, NP
Nurse Practitioner · Chubbuck, IDNPI 1255567210
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 461 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,149, 2.1 times the $1,026 reported in 2021. Among nurse practitioner clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 461 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$961
- Alkermes, Inc.$732
- Teva Pharmaceuticals USA, Inc.$689
- Neurocrine Biosciences, Inc.$496
- plus $2K from 19 others
What the payments were for
- Food & beverage$7,63099%
- Education$1111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 88 | $1,409 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 66 | $1,118 |
| Otsuka America Pharmaceutical, Inc. | 52 | $961 |
| Alkermes, Inc. | 48 | $732 |
| Teva Pharmaceuticals USA, Inc. | 55 | $689 |
| Neurocrine Biosciences, Inc. | 33 | $496 |
| Johnson & Johnson | 17 | $478 |
| Vanda Pharmaceuticals Inc. | 21 | $388 |
| Supernus Pharmaceuticals, Inc. | 11 | $236 |
| Ironshore Pharmaceuticals Inc. | 10 | $183 |
| Corium, LLC | 18 | $166 |
| Axsome Therapeutics, Inc. | 7 | $128 |
| Tris Pharma Inc | 1 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $106 |
| Lundbeck LLC | 6 | $105 |
| Abbott | 1 | $88 |
| Sunovion Pharmaceuticals Inc. | 5 | $65 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $55 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Indivior Inc. | 3 | $47 |
| Eisai Inc. | 2 | $36 |
| Collegium Pharmaceutical, Inc. | 2 | $32 |
| Tempus AI, Inc | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Braeburn Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$150
- INVEGA TRINZA$150
- VRAYLAR$125
- Onyda XR$117
How this compares
$7,741 in reported general payments places this provider in the 95th percentile of 570 nurse practitioner providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 55 | $165,959 |
| VraylarCariprazine Hcl | 112 | $152,738 |
| AustedoDeutetrabenazine | 24 | $91,215 |
| TrintellixVortioxetine Hydrobromide | 78 | $40,573 |
| Risperdal ConstaRisperidone Microspheres | 13 | $33,394 |
| Paliperidone ErPaliperidone | 72 | $30,102 |
| Abilify MaintenaAripiprazole | 11 | $29,705 |
| SpravatoEsketamine Hcl | 13 | $27,244 |
| RexultiBrexpiprazole | 16 | $21,215 |
| CaplytaLumateperone Tosylate | 11 | $18,827 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $17,484 |
| Lurasidone Hcl | 47 | $9,579 |
| VyvanseLisdexamfetamine Dimesylate | 22 | $8,147 |
| BelsomraSuvorexant | 16 | $7,245 |
| Olanzapine | 126 | $6,865 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta, Spravato | $478 | $226,59781 claims |
| AbbVieVraylar | $1,409 | $152,738112 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $689 | $91,21524 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $961 | $50,92027 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $106 | $48,720100 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,118 | $18,82711 claims |
| Eisai Inc.Dayvigo | $36 | $3,17111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 570 nurse practitioner providers in Idaho.
Other nurse practitioner in Chubbuck
- Brandon SmithChubbuck$3K
- Kathleen CliffordBoise$119K
- Alissa HelvikCoeur D Alene$93K
- Amanda ThompsonIdaho Falls$67K
- Micalena PerkinsBurley$44K
- Tosha JohnsonNampa$26K
- Loreen NugentBoise$20K
- Rachel RyanMeridian$19K
- Stephanie HartPost Falls$18K
- Joshua ScovilleTwin Falls$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.